NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSELA (trilaciclib) is an intravenous CDK4/6 inhibitor approved in February 2021 for small cell lung cancer and breast cancer. It is designed to preserve bone marrow function and reduce chemotherapy-induced myelosuppression in cancer patients. The drug works by modulating cell cycle checkpoints to protect hematopoietic stem cells during cytotoxic chemotherapy.
$80KPart D
Peak14.5 years to LOECOSELA is in peak lifecycle stage but shows minimal Medicare claims volume ($80K in 2023), suggesting limited market penetration and a small commercial team focused on specialty oncology adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Started Mar 2026
120 enrolled
Limited Stage Small Cell Lung Cancer
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Started Jan 2024
36 enrolled
Metastatic Triple-Negative Breast Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Started Oct 2023
302 enrolled
Extensive-stage Small-cell Lung Cancer
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Started Jun 2017
107 enrolled
Small Cell Lung Cancer
Worked on COSELA at Pharmacosmos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.